非小细胞肺癌生物标志物的研究进展

Research progress of biomarkers for non-small cell lung cancer

肺癌是全球癌症相关死亡的主要原因。尽管通过筛查高危人群进行早期检测越来越普遍,但大多数肺癌患者确诊时已是晚期。在过去10年中,非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗有了显著进步。新出现的靶向治疗和免疫治疗方案已使NSCLC治疗更具个体化,这显著影响了NSCLC患者的病程和结局。目前,分子生物标志物已经成为诊断癌症、预测治疗反应结果和评估预后的有利工具。本文总结了NSCLC诊断、预测和预后相关的生物标志物以及新型潜在预测性生物标志物。

Lung cancer is the leading cause of cancer-related deaths worldwide.Despite growing efforts for its early detection by screening populations at risk,the majority of lung cancer patients are still diagnosed in an advanced stage.In the last decade,the treatment of non-small cell lung cancer(NSCLC)has been improved significantly.Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach,significantly influencing the clinical course and outcome of the disease.At present,molecular biomarkers are becoming a powerful tool for diagnosing cancer,predicting treatment response outcomes,and assessing prognosis.In this review,we summarized the biomarkers relevant to the diagnosis,prediction,and prognosis of NSCLC as well as promising novel predictive biomarkers in the future.